A Multicenter, Randomized, Double-blinded, Placebo-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Placebo on Radiation Pneumonitis in Unresectable Non-small Cell Lung Cancer Patients Treated With Curative Concurrent Chemoradiotherapy Using Paclitaxel and Carboplatin
Latest Information Update: 07 Nov 2022
At a glance
- Drugs HL 301 (Primary)
- Indications Pneumonitis
- Focus Therapeutic Use
- Sponsors Hanlim Pharmaceutical
- 24 Nov 2020 New trial record